Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study
Open Access
- 28 May 2026
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , 3246-3256
Abstract
Aim: We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods: We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS‐CoV‐2 vaccination. Results: In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2–4.8], p = .015 and OR 1.8 [95% CI 1.3–2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome‐wide analysis. In the register study, people with a thrombophilia diagnosis had a five‐fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98–6.44]. Conclusion: Well‐characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS‐CoV‐2 immunization. Further research is recommended to elucidate their potential role in vaccine‐related thromboembolic events.Keywords
Funding Information
- Hjärt-Lungfonden (20200777)
- Vetenskapsrådet (2018‐03307)
- Vetenskapsrådet (2021‐05450)
- Vetenskapsrådet (2022‐01109)
- Vetenskapsrådet (2021‐05045)
- Uppsala Universitet
- Forskningsrådet för hälsa, arbetsliv och välfärd (2024‐01711)
- Knut och Alice Wallenbergs Stiftelse (KAW 2020.0182)
- Knut och Alice Wallenbergs Stiftelse (2020.0241)
- Knut och Alice Wallenbergs Stiftelse (2021‐0010/VC2021.0018)
- Knut och Alice Wallenbergs Stiftelse (2020.0299/VC 2022.0008)
This publication has 22 references indexed in Scilit:
- Pulmonary embolism after SARS-CoV-2 vaccinationVaccine: X, 2024
- COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individualsVaccine, 2024
- Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US AdultsJAMA Network Open, 2023
- Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.Vaccine, 2023
- SweGen: a whole-genome data resource of genetic variability in a cross-section of the Swedish populationEuropean Journal of Human Genetics, 2017
- Next-generation genotype imputation service and methodsNature Genetics, 2016
- Lifetime Risk of Venous Thromboembolism in Two Cohort StudiesThe American Journal of Medicine, 2016
- The Swedish Twin Registry: Establishment of a Biobank and Other Recent DevelopmentsTwin Research and Human Genetics, 2012
- Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a MutationJAMA, 2009
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994